Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Cancer Metabolism Based Therapeutics Market - Global Industry Insights, 2018–2026

Author: Abhijit Ranjane
by Abhijit Ranjane
Posted: Feb 07, 2019
cancer metabolism

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/961

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories,,By Drug –,,CPI-613,Enasidenib,By Indication –,,Acute Myeloid Leukemia (AML),Myelodysplastic Syndromes (MDS),Metastatic Renal Cell

Read Full Report with TOC @ www.coherentmarketinsights.com/ongoing-insight/toc/961

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories By Drug – CPI-613, Enasidenib,. By Indication – Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Metastatic Renal Cell Carcinoma, Melanoma, Others,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

About the Author

Contact US: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel : +1-206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Abhijit Ranjane

Abhijit Ranjane

Flag of United States
United States

Member since: May 31, 2017
Published articles: 376

Related Articles